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Abstract 
Purpose: To evaluate the antidiabetic, antihyperlipidemic and antioxidant activities of Buchanania 
lanzan. 
Methods: Wistar rats were divided into nine groups of six animals each, and 40 mg/kg of streptozotocin 
or streptozotocin + nicotinamide was administered intraperitonially to induce types I and II diabetes. 
Those with blood glucose levels > 190 ± 8 mg/dl were administered the methanol leaf extract of 
Buchanania lanzan (MEBL, 100 or 200 mg/kg, p.o.) or positive control for 21 days. Blood glucose, lipid 
profile, antioxidant enzymes and oxidative stress markers were evaluated. 
Results: Following induction, blood glucose level rose to 327.7 ± 47.4 mg/dl, compared to the normal 
value of 910 ± 3.2 mg/dl. Administration of MEBL (100 or 200 mg/kg) significantly (p < 0.05) decreased 
blood glucose level, serum lipid profile, and significantly (p < 0.05) increased antioxidant activity as 
evidenced by increase in super oxide dismutase (SOD), catalase, glutathione (GSH), and decrease in 
the activity of lipid peroxidation (LPO). 
Conclusion: MEBL exhibits antidiabetic, antihyperlipidemic and antioxidant activities in diabetic rat and 
needs to be further investigated for the treatment of both types I and II diabetes mellitus. 
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Diabetes mellitus is a chronic metabolic disease 
caused by an absolute or relative lack of insulin 
and or reduced insulin activity, which results in 
hyperglycemia and abnormalities in 
carbohydrate, protein and fat metabolism. 
Hyperlipidemic condition is metabolic 
complication of both clinical and experimental 
diabetes [1]. Low density lipoprotein in diabetic 
patients leads to abnormal metabolism and is 
associated with increase in very low density 
lipoprotein (VLDL) secretion and impaired VLDL 
catabolism. Ultimately, this leads to 
atherosclerotic plaque formation. Patients with 
diabetic mellitus are more likely to develop 
microvascular and macrovascular complications 
than the non diabetic population. Though 
different types of oral hypoglycaemic agents are 
available along with insulin for the treatment of 
diabetes mellitus, there is growing interest in 
herbal remedies due to the side effects 
associated with these therapeutic agents [2]. The 
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investigation of anti-diabetic agents of plant 
origin which are used in traditional medicine is 
thus of great importance. 
 
Management of diabetes with synthetic drugs is 
costly and chances of side effects are high. 
Therefore, it is prudent to look for options in 
herbal medicines for diabetes as well. Some 
active principles present in medicinal plants have 
been reported to possess pancreatic beta cells 
regenerating, insulin releasing and fighting the 
problem of insulin resistance [3]. It is claimed, not 
only in Ayurveda, but also in several other 
traditional systems of medicine, that plants useful 
in diabetes management also possess strong 
antioxidant/free-radical scavenging properties [4]. 
Free radicals meet many of the criteria required 
for a role in the pathogenesis of diabetic 
syndrome [6].  
 
Buchanania lanzan Spreng (locally called as 
Chironji), a member of family Anacardiaceae is a 
commercially useful tree species found in several 
areas of India. The plant has well-known 
traditional uses and its seeds are used as 
expectorant and tonic. The oil extracted from 
kernels is applied on skin diseases and also to 
remove spots and blemishes from the face. The 
root is used as expectorant, in biliousness and 
also for curing blood diseases. The juice of the 
leaves is digestive, expectorant, aphrodisiac and 
purgative. The rhizome of B. lanzan finds an 
important place in indigenous medicine as an 
expectorant, diuretic and carminative. It is also 
found to have anticancer, antihypertensive, 
larvicidal and anti-diabetic activities [7-10]. The 
present study was carried out to evaluate the 
antidiabetic, antihyperlipidemic and antioxidant 
activity of the methanol extract of Buchanania 
lanzan in streptozotocin-induced types I and II 






Streptozotocin was purchased from Himedia 
Research Laboratories, Mumbai, India. 
Nicotinamide was purchased from Sisco 
Research Laboratories, Mumbai, India.  Assay 
kits for serum triglycerides (TGL), total 
cholesterol (TC) and high density lipoproteins 
(HDL) were obtained from Coral Diagnostics Ltd, 
Mumbai, India. All other chemicals used were of 
analytical grade. 
 
Plant material and preparation of extract  
 
The leaves of Buchanania lanzan were obtained 
from the local market and authenticated by  
V. Krishna Rao of Kovel Foundation, 
Visakhapatnam, India. Voucher number of the 
specimen is KF VS 7274 and the specimen is 
kept in the herbarium of Kovel Foundation, 
Visakhapatnam. 
 
The leaves were air-dried and then powdered. 
Lipids were removed via petroleum ether 
extraction by maceration method. It was then 
filtered and the filtrate discarded. The residue 
was successively extracted with methanol (99%) 
using a Soxhlet apparatus. The solvent was 
completely evaporated under reduced pressure 
and the dry extract dissolved in normal saline 




Male albino Wistar rats (aged, 4 months; body 
weight, 180 ± 10 g), used in the study, were 
procured from Sainath Enterprises, Hyderabad, 
India. The animals were housed in polyacrylic 
cages with not more than six animals per cage, 
at an ambient temperature of 18 ± 2 0C and 12 h 
light/12 h-dark cycle. The rats had free access to 
standard chow diet and water ad libitum. The 
care and handling of the animals were carried 
out as per the approved guidelines of the 
Committee for the Purpose of Control and 
Supervision of Experiments on Animals 
(CPCSEA), New Delhi and OECD TG 452. [19]. 
The research protocols were approved by the 
Institutional Animal Ethical Committee (IAEC) as 
per approval ref no. 1028/SPIPS/Wgl/IAEC/2011. 
 
Acute toxicity study 
 
Acute toxicity assay was performed in rats 
according to OECD 423 guidelines [20] and no 
lethality was found in any of the groups after 




Nine groups of six animals each were used for 
study. Group I animals served as normal control 
rats and received normal saline. Group II served 
as type I diabetic control and received 
streptozotocin (40 mg/kg, ip). Group III was type-
II diabetic control and received streptozotocin 
and nicotinamide (230 mg/kg, ip) Group IV 
animals were type I diabetic rats treated with 100 
mg/kg of the extract of Buchanania lanzan 
(MEBL) while Group V animals were type-II 
diabetic rats treated with 100 mg/kg of MEBL 
Group VI served as type I diabetic treated with 
200 mg/kg of MEBL, Group VII were type II 
diabetic rats treated with 200 mg/kg of MEBL; 
Group VIII animals were type I diabetic rats 
treated with the standard drug, insulin (4 IU/kg, 
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sc) [2] while Group IX type II diabetic rats treated 
with the standard drug, glibenclamide (0.5 mg/kg, 
orally) [2]. 
 
Induction of type I diabetes 
 
A single dose of streptozotocin (40 mg/kg, ip) 
was administered to Groups II, IV, VI, and VIII 
rats. While normal control rats were injected with 
saline alone. Streptozotocin was dissolved in 
freshly prepared 0.1M citrate buffer (pH 4.5).[11] 
Streptozotocin-injected animals were given 5 % 
glucose for 24 h to prevent initial streptozotocin-
induced hypoglycemic mortality [11].  
 
Induction of type II diabetes (T2DM) 
 
Experimental T2DM was induced in groups III, V, 
VII and IX rats by administering nicotinamide 
(NA, 230 mg/kg, ip, dissolved in normal saline) 
15 min prior to  administration of Streptozocin 
(STZ, 40 mg/kg, ip, freely dissolved in 0.1M 
citrate buffer pH 4.5).  
 
Blood glucose was evaluated 3 days later and 
the animals with glucose level > 190 ± 8 mg/dl 
were selected for the study. The reference drugs 
and extract were administered once daily for 21 
days. Blood glucose level was monitored on days 
7, 14 and 21. 
 
Assessment of biochemical parameters 
 
After 21 days of the experiment, blood samples 
were collected by retro orbital sinus puncture, 
under mild ether anaesthesia from all the 
animals. Then the blood samples were 
centrifuged at 3000 rpm for 15 min and serum 
was collected. The collected serum was used for 
the evaluation of biochemical parameters.  
 
Whole blood was used to determine glucose 
concentration with the aid of a glucometer [11] 
with reagent strips (Aspen Diagnostics (P) Ltd, 
Delhi, India). Serum total cholesterol (TC), high 
density lipoprotein (HDL), low density lipoprotein 
(LDL) and triglycerides (TG) were measured 
using a standard kit (Coral Laboratories) [12]. 
The amount of lipid peroxidation products (LPO) 
present in serum was determined by 
thiobarbituric acid reactive substances (TBARS) 
method, which measures malondialdehyde 
(MDA) reactive products using UV-visible 
spectroscopy (SL-150, Elico Ltd, India) at 
532 nm. LPO was expressed in nmol/mg protein 
[13]. Superoxide dismutase (SOD) in serum was 
determined using photo-oxidation method [14]. 
Change in absorbance was recorded 
spectrophotometrically at 460 nm for 4 min and 
SOD was expressed in nmol/mg protein. 
Glutathione was determined spectrophoto-
metrically at a wavelength of 319 nm based on 
the formation of a coloured complex between 
glutathione and 5,5'-dithiobis-(2-nitrobenzoic acid 
(DTNB) [15]. Glutathione was expressed in 
µmol/mg pr. Catalase measurement was carried 
out based on the ability of catalase to oxidize 
hydrogen peroxide [16].  The change in 
absorbance of hydrogen peroxide solution was 
measured at 240 nm for 3 min at 1 min interval. 
On decomposition of hydrogen peroxide by 
catalase, the absorbance decreases with time. 




Statistical analysis was done by using one way 
and two way ANOVA followed by Bonferroni’s 
multiple comparison using Graph Pad Prism 
software, version 5.0 test Spreng (Graph Pad 
Software, Inc, USA). All results are expressed as 
mean ± SEM. A probability of p < 0.05 was 




Effect of MEBL on blood glucose level  
 
Diabetes induction using STZ showed significant 
hyperglycaemia in both types I and II diabetic 
groups. Oral administration of the MEBL (100 
and 200 mg/kg) and the standard drugs (insulin 
and glibenclamide) for 21 days significantly (p < 
0.05) lowered blood glucose levels (Table1). The 
effect was dose-dependently. 
 
Effect of MEBL on serum lipid profile of type I 
and type II diabetic rats 
 
The levels of LDL, VLDL, cholesterol and 
triglycerides in types I and II diabetic rats 
significantly (p < 0.05) increased following 
treating with streptozotocin while HDL levels 
decreased significantly (p < 0.05), when 
compared with normal control (Table 2). 
Treatment with standard drugs (insulin and 
glibenclamide) and MEBL produced significant (p 
< 0.05) decrease in LDL, VLDL, cholesterol and 
triglycerides, but a significant (p < 0.05) increase 
in HDL levels, compared to diabetic control 
groups. 
 
Effect of MEBL on antioxidant activity in 
diabetic rats 
 
The results for the anti-oxidant activity of the 
extract are shown in Table 4. Both the extract 
and reference drugs significantly (p < 0.05) 
reduced altered LPO damage. The lowest 
activities of CAT, SOD and GSH was seen in the 
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Table I: Effect of MEBL on blood glucose level (mean ± SEM, n = 6) of diabetic rats 
 
Blood glucose level (mg/dL)  
Group Pre-STZ Day 0 Day 7 Day 14 Day 21 
I (Normal control) 101.66±4.70 109.66±4.84 117.00±0.57 111.33±1.20* 115.66±5.23* 
II (Diabetic control, 
Type, I) 
91.00±3.21 327.66±47.41* 353.66±46.00* 381.66±40.44* 405.33±27.51* 
III (Diabetic control, 
Type II)  
105.00±8.73 511.33±120.57* 429.00±91.000* 254.66±60.93* 109.66±40.17* 
IV (Extract 100mg, 
Type I) 
79.66±7.17 213.66±5.81 243.66±6.88 270.33±7.21 357.33±3.18 
V (Extract 100mg, 
Type II) 
130.66±19.83 335.00±14.10 259.66±31.15 149.33±10.68 119.00±4.72* 
VI (Extract 200mg, 
Type I) 
95.66±10.08 425.33±79.68* 337.66±64.15 303.33±73.60 154.66±22.21* 
VII (Extract 200mg, 
Type II)   
86.33±13.59 272.00±59.80 203.33±26.03 169.33±21.85 129.66±20.34* 
VIII (STZ+INS 103.66±9.93 392.66±176.68 293.33±104.83 208.33±43.09 111.33±8.11* 
IX (STZ+NIC+GLI) 90.33±7.21 392.33±61.86* 352.33±53.45 176.33±28.98 137.66±23.82* 
 
*p < 0.05, Type 1 and Type II diabetic controls were compared to normal control. Test and standard groups were compared to 
respective diabetic control groups.
Table 2: Effect of MEBL on serum lipid profile of type I and type II diabetic rats  
 
Serum  lipid level 
HDL (mg/dl) LDL (mg/dl) 
Group 
Day 0 Day 21 Day 0 Day 21 
I (Normal control) 21.66±1.45 21.33±1.76b 53.46±1.75 51.33±1.34b 
II (Diabetic control, Type I) 20.33±1.20 8.66±1.20 55.73±3.16 59.66±9.35 
III (Diabetic control, Type II)  18.33±2.90 10.33±2.33 61.66±5.50 85.20±13.11 
IV (Extract 100mg, Type I) 21.66±1.20 26.00±1.15c 54.20±0.41 33.8 ±7.05a 
V (Extract 100mg, Type II) 18.00±2.30 26.00±1.15d 62.00±3.52 42.06±2.22c 
VI (Extract 200mg, Type I) 20.33±2.02 21.00±1.15b 54.00±4.10 42.46±2.71 
VII (Extract 200mg, Type II) 19.66±1.66 20.00±0.57a 54.46±5.42 44.60±4.42c 
VIII (STZ+INS 22.66±2.02 25.33±1.76c 51.20±3.06 34.00±0.91a 
IX (STZ+NIC+GLI) 19.00±2.08 24.66±1.76c 59.33±7.51 40.73±3.65c 
 
Note: HDL = high density lipoproyein; LDL = low density lipoprotein 
 





VLDL (mg/dl) TGL (mg/dl) CHOL (mg/dl) 
 Day 0 Day 21 Day 0 Day 21 Day 0 Day 21 
I (Normal 
control) 
13.53±0.37 14.66±0.29d 67.66±1.85 73.33±1.45d 88.66±0.88 87.33±1.45d 
II (Diabetic 
control, Type I) 
14.60±0.92 6.33±3.03 73.00±4.61 231.66±15.16 90.66±2.90 114.66±7.0
5 
III (Diabetic 
control, Type II)  
16.33±0.76 42.46±2.17 81.66±3.84 212.33±10.86 96.33±3.28 138.00±10.
39 
IV (Extract 
100mg, Type I) 
16.46±1.34 16.60±0.34c 82.33±6.74 83.00±1.73c 92.33±1.76 76.66±5.60c 
V (Extract 
100mg, Type II) 
15.33±0.92 18.60±0.34d 76.66±4.63 93.00±1.73d 95.33±2.18 86.66±1.20d 
VI (Extract 
200mg, Type I) 
14.66±1.37 23.20±1.00c 73.33±6.88 116.00±5.03c 89.00±3.78 86.66±2.02b 
VII (Extract 
200mg, Type II)  
19.20±0.41 27.40±1.32d 96.00±2.08 137.00±6.65d 93.33±6.22 92.00±6.02d 
VIII (STZ+INS 15.13±0.69 18.00±0.91c 75.66±3.48 90.00±4.58c 89.00±1.73 77.33±1.76c 
IX 
(STZ+NIC+GLI) 
17.00±0.83 18.60±1.70d 85.00±4.16 93.00±8.54d 95.33±8.81 85.00±3.21d 
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Table 4:  Effect of MEBL on antioxidant enzyme levels  
 
Data are expressed as mean ± SEM (n = 6); a p < 0.001, b p < 0.01, c p < 0.05 compared with treated and normal diabetic and 
control groups 
 
diabetic rats both types I and II). However, 
following treatment with the extract (both doses) 
normalized (p < 0.05) the altered antioxidant 





The present study was undertaken to evaluate 
the antidiabetic, antihyperlipidemic and 
antioxidant activity of methanolic extract of 
Buchanania lanzan in Streptozotocin induced 
types I and II diabetic rats. Streptozotocin was 
given to rats for induction of diabetes and it is 
known that streptozotocin is toxic to cells by 
causing damage to the DNA, though other 
mechanisms may also contribute. DNA damage 
induces activation of poly-ADP-ribosylation, 
which is likely more important for diabetes 
induction than DNA damage itself. Nicotinamide 
(NA) is given before giving streptozotocin to 
induce type II diabetes and nicotinamide is 
proved to be effective in protecting pancreatic 
islets by inhibition of PARP-1 activity. NA inhibits 
this enzyme, preventing depletion of NAD(+) and 
ATP in cells exposed to STZ. Moreover, NA 
serves as a precursor of NAD(+) and thereby 
additionally increases intracellular NAD(+) levels. 
[21]  
 
Administration  of extract for 21 days  resulted in 
significant diminution of fasting blood glucose 
level in comparison with  diabetic rats. The 
presence of abundant flavonoids may be 
responsible for its activity. It was observed that 
there was increase in serum levels of glucose, 
triglycerides, total cholesterol, VLDL and LDL-C 
with a concomitant decrease in serum HDL-C in 
STZ-induced types I and II diabetes. Its effect on 
the triglycerides is likely to increase the risk of 
developing coronary heart disease [17]. It is 
noteworthy, however, that the extract significantly 
restored the serum lipids of both types I and II 
diabetic rats to their pre-diabetic levels. Oxidative 
stress is produced under diabetic conditions and 
it is likely to be involved in the progression of 
pancreatic β-cell dysfunction. Also, because of 
the relatively low expression of antioxidant 
enzymes, such as catalase and superoxide 
dismutase, pancreatic β- cells may be vulnerable 
to reactive oxygen species ROS attack when the 
system is under oxidative stress. It was observed 
that there was a decrease in the activity of 
antioxidant enzymes - superoxide dismutase 
(SOD), catalase (CAT), glutathione peroxidise 
(GPx) - in the serum of the diabetic rats.  
However, the extract restored the activity of 
these enzymes. [20].  
 
It has been shown that dietary supplementation 
with natural antioxidants such as vitamins C and 
E, melatonin and flavonoids attenuated the 
oxidative stress and diabetic state induced by 
STZ. Ancient literature claim that the leaves of 
Buchanania lanzan may contain glycosides, 
carbohydrates, sterols and flavonoids which may 
have anti-diabetic activity [21]. Therefore, the 
antidiabetic, antihyperlipidemic and antioxidant 
activities of this plant may due to its active 
constituents, including glycosides, 




Administration of the methanol extract of 
Buchanania lanzan produced antidiabetic, 
Antihyperlipidemic and antioxidant activities. 
However, further phytochemical and 
Group Antioxidant  enzyme 
 Lipid Peroxidation 




 (mg%, 10-3) 
SOD 
(unit/mg protein) 
I (Normal control) 0.61±0.05a 155.1±6.5a 0.0080±0.0009a 0.291±0.025b 
II (Diabetic control, 
Type, I) 
7.212±1.3 17.68±3.0 0.0024±0.0003 0.078±0.01 
III (Diabetic control, 
Type II)  
5.242±1.0 30.31±5.4 0.0025±0.0004 0.069±0.022 
IV (Extract 100mg, 
Type I) 
0.66±0.00a 120.7±7.9 b 0.0063±0.0001 a 0.286±0.009 b 
V (Extract 100mg, 
Type II) 
0.80±0.11a 134.3±8.5b 0.0065±0.0004c 0.289±0.011b 
VI (Extract 200mg, 
Type I) 
1.78±0.42 a 104.7±19.7 b 0.0043±0.0001 0.159±0.030 
VII (Extract 200mg, 
Type II)  
0.88±0.10b 99.78±16.4c 0.0052±0.0011 0.117±0.025 
VIII (STZ+INS 0.70±0.00 a 111.3±20.0b 0.0055±0.0003 b 0.233±0.043c 
IX (STZ+NIC+GLI) 0.88±0.10a 129.7±19.8b 0.0059±0.0011 0.246±0.046b 
225 
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pharmacological investigations are required to 
elucidate the detailed mechanisms of action of 
the extract as well as identify the active 
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